If all goes well, thanks to artificial intelligence, we may soon have a new AI-synthesized drug capable of assisting OCD patients in managing their symptoms and thus leading normal lives.
The Alkermes ALKS 3831 development program is part of our ongoing commitment to develop new therapeutic options for adults living with serious mental illness.